Spinal Stabilization Technologies Launches Pioneering IDE Trial for PerQdisc Device in the U.S.

Spinal Stabilization Technologies Initiates IDE Trial for PerQdisc Device

Spinal Stabilization Technologies, LLC (SST) has reached a crucial milestone in the realm of spinal care. The company recently announced the commencement of its clinical trial for the PerQdisc Nucleus Replacement Device (NRD) by enrolling the first patient in the United States. This important step marks the beginning of SST's initiative to assess its innovative technology for treating degenerative disc disease (DDD).

The announcement was made in San Antonio on March 3, 2025, where Dr. Pierce Nunley, a leading figure in spinal surgery, successfully performed the first U.S. PerQdisc procedure. During this event, Dr. Nunley highlighted the promising outcomes observed in previous feasibility trials, where over 40 patients had been treated with the PerQdisc system. According to him, the results concerning pain reduction and overall clinical improvement have been exceptional. He emphasized that the procedure itself is straightforward, with expectations of a quick recovery period.

The PerQdisc device is designed to replace the nucleus pulposus of a single lumbar disc (from L1 to L5), which aims to alleviate pain while preserving spinal motion. Current surgical options for patients suffering from painful lumbar DDD are limited, often leading to spinal fusion procedures that reduce mobility and exert additional stress on adjacent vertebral levels. The PerQdisc technology offers a non-fusion alternative that aims to keep the surrounding anatomy unharmed.

To facilitate this trial and expedite the regulatory approval process for the PerQdisc system, SST has successfully secured $17 million in funding from both existing and new investors. This financial backing not only demonstrates strong confidence in SST's innovative technology but also serves to further advance clinical development initiatives.

In addition to this significant trial milestone, SST announced the appointment of Dr. Frank Phillips to its Board of Directors. Dr. Phillips is an eminent spine surgeon with vast experience and has been actively involved in advancing minimally invasive surgical techniques. With over 200 publications to his name and having trained numerous spine specialists, his insights and leadership will be invaluable as SST tracks its strategic course and enhances clinical adoption of the PerQdisc device.

Mark Novotny, CEO of SST, expressed excitement regarding these developments, stating that with robust clinical outcomes, an experienced team, and Dr. Phillips’s inclusion in their board, SST is poised to bring the PerQdisc device to a patient demographic seeking improved treatment options. Novotny’s optimism is bolstered by the potential of the PerQdisc technology to change the therapeutic landscape for individuals suffering from discogenic low back pain, offering a safer, minimally invasive method to improve their function and alleviate discomfort.

Additionally, SST has maintained commitment towards evidence-based medicine, complementing their innovative advancements with a solid intellectual property portfolio. The company aims to lead the way in spine surgery, prioritizing minimally invasive solutions that not only enhance patient care but also foster advancements in clinical practices.

In summary, the launch of the IDE trial is a crucial step towards creating effective alternatives for patients battling degenerative disc disease. As SST continues to develop its groundbreaking PerQdisc Nucleus Replacement Device, the potential for improved clinical outcomes and enhanced patient mobility remains promising. The company urges stakeholders and the medical community to stay tuned for updates as they progress through this pioneering clinical trial.